Page 2449 - Williams Hematology ( PDFDrive )

2420 Index Index 2421

Cyclin-dependent kinase 4 inhibitors gene, in reduced-intensity conditioning, 360 in combination chemotherapy, 327
1465 for Waldenström macroglobulinemia, for diffuse large B-cell lymphoma, 1628,
Cyclin-dependent kinase 7 (cdk7), 216 1794–1795 1629t, 1631
Cyclin-dependent kinase 8 (cdk8), 216 Cycloserine, megaloblastic anemia and, 606t high-dose, 331t
Cyclin-dependent kinase 9 (cdk9), 216 Cyclosporine for Hodgkin lymphoma, 1616
Cyclin-dependent kinase 10 (cdk10), 216 adverse effects, 2262 for juvenile myelomonocytic leukemia,
Cyclin-dependent kinase 11 (cdk11), for aplastic anemia, 523–524, 525f, 525t, 1471
216–217 527 for Langerhans cell histiocytosis, 1106,
Cyclin-dependent kinase inhibitors (CDKIs), for autoimmune hemolytic anemia, 840, 1107
217–218, 1539 1541 for mantle cell lymphoma, 1656, 1658t,
Cyclin E, 215 for Diamond-Blackfan anemia, 540 1659t
Cyclins, 213–216, 214f, 215t for drug resistance in acute myelogenous mechanism of action, 321
Cyclooxygenase (COX)-1, 403, 1857f, 1876, leukemia, 1404 megaloblastic anemia and, 606t
1969–1970, 2073–2074 for familial hemophagocytic for myelodysplastic syndromes,
Cyclooxygenase (COX)-1b, 2073 lymphohistiocytosis, 1228 1358–1359, 1361
Cyclooxygenase (COX)-1 inhibitors, 404 for hemophagocytic lymphohistiocytosis, pharmacology, 321–322
Cyclooxygenase (COX)-2, 404, 1876, 1970, 1115 for primary myelofibrosis, 1330
2073–2074 for immune thrombocytopenia, 2007 resistance to, 319t
Cyclooxygenase (COX)-2 inhibitors, 2075, for IPEX syndrome, 1223 for transient myeloproliferative disorder,
2121 for large granular lymphocytic leukemia, 1386
Cyclooxygenase (prostaglandin H 1567 Cytidine 5-triphosphate synthase 1 (CTPS1)
2
synthase-1) deficiency, 2058 for myelodysplastic syndromes, 1359 deficiency, 1220–1221
Cyclophosphamide. See also BEACOPP for primary myelofibrosis, 1329 Cytochrome b, 621t, 1013t, 1014, 1029
regimen; CHOP regimen; for pure red cell aplasia, 544 Cytochrome b deficiency, 790
5
CODOX-M/IVAC regimen; in reduced-intensity conditioning, 360 Cytochrome b reductase, 701t
5
COPP regimen; EPOCH regimen; for thrombotic thrombocytopenic Cytochrome b reductase deficiency. See also
5
HyperCVAD regimen purpura, 2257 Methemoglobinemia
for acute lymphoblastic leukemia, 1515, CYLD (CYLD), 233t, 1711, 1737 clinical features, 793
1516 CYP2C9, 395 epidemiology, 789
adverse effects, 331, 368, 1407, 1519t CYP2C19, 1850, 2076 etiology and pathogenesis, 789–790
for AL amyloidosis, 1761, 1780–1781 CYP enzymes heterozygosity for, 790
for α-heavy-chain disease, 1808 acute intermittent porphyria and, 901 laboratory features, 792
for antiphospholipid syndrome, 2245 porphyria cutanea tarda and, 906 treatment, 793
for aplastic anemia, 526, 527 Cysteine aspartyl-specific proteases. See Cytochrome c (Cyt-c), 204f, 205
for autoimmune hemolytic anemia, 839 Caspases Cytogenetics, 173–188. See also
for Burkitt lymphoma, 1675, 1675t, 1676 Cytarabine (ara-C), 321–322. See also Chromosomal abnormalities
for chronic lymphocytic leukemia, 1534, CODOX-M/IVAC regimen; in aplastic anemia, 520
1535, 1537 ESHAP regimen cell preparation methods, 173–174
for diffuse large B-cell lymphoma, 1629t for acute lymphoblastic leukemia, 1515 chromosome nomenclature, 174, 175t
for follicular lymphoma, 1645t, 1646 or acute lymphoblastic leukemia, 1516 metaphase, 1711–1712
for γ-heavy-chain disease, 1806 for acute myelogenous leukemia, Cytokine release syndrome (CRS), 415–416,
before hematopoietic cell transplantation, 1394–1396, 1395t, 1398–1399, 1402t 1539
360 in children, 1409 Cytokines. See also specific cytokines
high-dose, before hematopoietic cell high-dose vs. standard-dose, 1396 for aplastic anemia, 526
transplantation, 331t, 332t, 360 in older patients, 1408 in apoptosis regulation, 209
for Hodgkin lymphoma, 1616 in pregnant patients, 1409 in B-cell precursor development, 270
for immune thrombocytopenia, 2007 for acute promyelocytic leukemia, 1404, in disseminated intravascular coagulation,
for large granular lymphocytic leukemia, 1405t 2200
1567 for adult Langerhans cell histiocytosis, in erythropoietic precursor development,
mechanism of action, 329 1108–1109 550
for μ-heavy-chain disease, 1810 adverse effects, 322, 1519t in extracellular matrix, 61–62, 62t
for mycosis fungoides, 1687 for chronic lymphocytic leukemia, for Fanconi anemia, 529
pharmacology, 330 1534 in hematopoietic stem cell regulation,
platelet function and, 2079 for chronic myelogenous leukemia, 1459 264–265, 264t
posttransplantation, 357 for chronic myelomonocytic leukemia, in innate immune response, 303
for pure red cell aplasia, 544 1469 in lymphopoiesis regulation, 1154

Kaushansky_index_p2393-2506.indd 2420 9/21/15 3:21 PM